(MENAFN- PR Newswire)
The anti-infective drug market is seeing strong growth due to multiple interrelated factors. One key driver is the rising incidence of specific infectious diseases, including healthcare-associated infections, sexually transmitted diseases (STDs), and respiratory infections. These health issues present major challenges worldwide, prompting healthcare systems to focus on finding effective treatments. At the same time, there is a surge in research, development, and clinical trials aimed at creating new therapies and improving the effectiveness of current drugs.
LAS VEGAS, Aug. 30, 2024 /PRNewswire/ -- DelveInsight's
Anti-Infective Drugs Market Insights
report provides the current and forecast market analysis, individual leading anti-infective drugs companies' market shares, challenges, anti-infective drugs market drivers, barriers, trends, and key market anti-infective drugs companies in the market.
Key Takeaways from the Anti-Infective Drugs Market Report
As per DelveInsight estimates, North America is anticipated to dominate the global anti-infective drugs market during the forecast period.
Based on the indication segment of the anti-infective drugs market, the lung cancer category is projected to register a significant growth in revenue in the Anti-Infective drugs market during the forecast period (2024–2030).
Notable anti-infective drugs companies such as Merck & Co., Inc., Gilead Sciences, Inc., GSK plc., Pfizer Inc., Alembic Pharmaceuticals, Mankind Pharma, Novartis AG, Abbott., Astellas Pharma d.o.o., Bayer AG, Bristol-Myers Squibb Company, Sanofi, Janssen Global Services, LLC, F. Hoffmann-La Roche Ltd, Cipla Inc., Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Xellia Pharmaceuticals, AbbVie Inc., Melinta Therapeutics LLC, PACIFIC INDIA PHARMA LIMITED, and several others, are currently operating in the anti-infective drugs market.
In May 2023 , the FDA approved Arexvy, the first vaccine for respiratory syncytial virus (RSV) available in the United States. Arexvy is approved for preventing lower respiratory tract disease caused by RSV in individuals aged 60 and older.
In May 2023, the FDA approved Xacduro (sulbactam for injection; durlobactam for injection), a new treatment for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii-calcoaceticus complex, for patients 18 years of age and older.
In December 2022, the FDA approved Sunlenca® (lenacapavir) as a first-in-class, twice-yearly treatment option for individuals living with multi-drug resistant HIV.
To read more about the latest highlights related to the anti-infective drugs market, get a snapshot of the key highlights entailed in the Global Anti-Infective Drugs Market Report
Anti-Infective Drugs Overview
Anti-infective drugs are a broad category of medications designed to combat infections caused by pathogens such as bacteria, viruses, fungi, and parasites. These drugs include antibiotics, antiviral agents, antifungal medications, and antiparasitics. Antibiotics, for instance, work by targeting specific bacterial functions or structures, thereby inhibiting the growth of bacteria or killing them outright. Each class of antibiotics, such as penicillins or tetracyclines, operates through different mechanisms and is used to treat various bacterial infections.
Antiviral drugs, on the other hand, focus on preventing the replication of viruses within host cells. Examples include drugs like acyclovir for herpesviruses or oseltamivir for influenza. Antifungal agents, such as fluconazole or itraconazole, target fungal cell walls or cellular processes, making them effective against fungal infections like candidiasis or aspergillosis. Similarly, antiparasitic drugs are used to treat infections caused by parasites, including protozoa and helminths, with medications like chloroquine for malaria or mebendazole for worm infections. The development and use of these drugs are crucial in managing and treating a wide range of infectious diseases, contributing significantly to public health.
Anti-Infective Drugs Market Insights
In 2023, North America had the largest share of the anti-infective drugs market compared to other regions. This is due to the rising demand for anti-infective medications driven by an increase in infectious and targeted diseases, a growing elderly population suffering from these conditions, heightened awareness initiatives, new drug launches, and the presence of major market players in the region.
Additionally, the U.S. Centers for Disease Control and Prevention (CDC) supports the use of antivirals for treating various infectious diseases. For example, in September 2021, the CDC endorsed four FDA-approved antiviral drugs for influenza treatment: oseltamivir phosphate, zanamivir, peramivir, and baloxavir marboxil. Such endorsements by government health organizations are expected to boost the anti-infective drugs market.
Furthermore, drug launches, regulatory approvals, acquisitions, and agreements in the region will also contribute to increased demand. For instance, Alembic Pharmaceuticals received FDA approval in January 2022 for Doxycycline Hyclate Delayed-Release Tablets, which help reduce drug-resistant bacteria development.
Overall, these factors combined are likely to create a favorable environment for the growth of the anti-infective drugs market in North America.
To know more about why North America is leading the market growth in the anti-infective drugs market, get a snapshot of the Anti-Infective Drugs Market Outlook
Anti-Infective Drugs Market Dynamics
The anti-infective drugs market is a dynamic and evolving sector driven by various factors. One of the primary dynamics is the ongoing battle against antibiotic resistance . As bacteria and other pathogens evolve, traditional antibiotics become less effective, prompting a significant demand for new and innovative anti-infective agents. This has spurred substantial investment in research and development (R&D) to discover novel drugs and treatments. Pharmaceutical companies are focusing on developing new classes of antibiotics, antivirals, antifungals, and antiparasitics to combat resistant strains and emerging infections.
Regulatory and policy changes also play a crucial role in shaping the market. Governments and health organizations worldwide are implementing stricter guidelines and policies to manage antibiotic use and promote responsible prescribing practices. These measures aim to curb the spread of resistance and incentivize the development of new drugs. Additionally, there is a growing emphasis on improving diagnostics to ensure the appropriate use of anti-infective medications, which influences market dynamics and investment strategies.
Economic factors and market access considerations further impact the anti-infective drugs market. High R&D costs , coupled with the need for extensive clinical trials , can be a barrier to entry for smaller companies. However, strategic partnerships, mergers, and acquisitions are common in this sector, allowing companies to pool resources and expertise. Market access and pricing pressures are also significant, as healthcare systems and insurers are increasingly scrutinizing drug prices and value propositions.
The global nature of infectious diseases underscores the international dimension of the anti-infective drugs market. Emerging infectious diseases, such as those caused by novel pathogens or pandemics, create urgent needs for effective treatments and vaccines. This global perspective drives international collaboration and competition among pharmaceutical companies and influences market trends and opportunities. Overall, the anti-infective drugs market is characterized by a complex interplay of scientific, regulatory, economic, and global factors that continuously shape its dynamics.
Get a sneak peek at the anti-infective drugs market dynamics @ Anti-Infective Drugs Market Dynamics Analysis
| Report Metrics |
Details |
| Coverage |
Global |
| Study Period |
2021–2030 |
| Anti-Infective Drugs Market CAGR |
~4% |
| Anti-Infective Drugs Market Size by 2030 |
~USD 175 Billion |
| Key Anti-Infective Drugs Companies |
Merck & Co., Inc., Gilead Sciences, Inc., GSK plc., Pfizer Inc., Alembic Pharmaceuticals, Mankind Pharma, Novartis AG, Abbott., Astellas Pharma d.o.o., Bayer AG, Bristol-Myers Squibb Company, Sanofi, Janssen Global Services, LLC, F. Hoffmann-La Roche Ltd, Cipla Inc., Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Xellia Pharmaceuticals, AbbVie Inc., Melinta Therapeutics LLC, PACIFIC INDIA PHARMA LIMITED, among others |
Anti-Infective Drugs Market Assessment
Anti-Infective Drugs Market Segmentation
Anti-Infective Drugs Market Segmentation By Type: Antibiotics, Antivirals, Antifungals, and Others
Anti-Infective Drugs Market Segmentation By Indication: HIV Infection, Pneumonia, Respiratory Viral Infection, and Others
Anti-Infective Drugs Market Segmentation By Route of Administration: Oral, Parenteral, Topical, and Others
Anti-Infective Drugs Market Segmentation By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and E-Commerce
Anti-Infective Drugs Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World
Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View
Which MedTech key players in the anti-infective drugs market are set to emerge as the trendsetter explore @ Anti-Infective Drugs Companies
Table of Contents
| 1 |
Anti-Infective Drugs Market Report Introduction |
| 2 |
Anti-Infective Drugs Market Executive Summary |
| 3 |
Competitive Landscape |
| 4 |
Regulatory Analysis |
| 5 |
Anti-Infective Drugs Market Key Factors Analysis |
| 6 |
Anti-Infective Drugs Market Porter's Five Forces Analysis |
| 7 |
Anti-Infective Drugs Market Layout |
| 8 |
Anti-Infective Drugs Market Company and Product Profiles |
| 9 |
KOL Views |
| 10 |
Project Approach |
| 11 |
About DelveInsight |
| 12 |
Disclaimer & Contact Us |
Interested in knowing the anti-infective drugs market by 2030? Click to get a snapshot of the
Anti-Infective Drugs Market Trends
Related Reports
Respiratory Syncytial Virus Market
Respiratory Syncytial Virus Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key RSV companies, including Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, among others.
Respiratory Syncytial Virus Pipeline
Respiratory Syncytial Virus Pipeline Insight – 2024
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key
respiratory syncytial virus companies, including GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, among others.
HIV Type-1 Market
HIV Type-1 Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key HIV Type-1 companies, including MacroGenics, CytoDyn, Inc., ViiV Healthcare, GlaxoSmithKline, PPD, Excision BioTherapeutics, TaiMed Biologics Inc., Gilead Sciences, ST Pharm Co., Ltd., Merck Sharp & Dohme LLC, Janssen Sciences Ireland UC, Vir Biotechnology, Inc., National Institute of Allergy and Infectious Diseases (NIAID), AbbVie, Sanofi, ModeX Therapeutics, among others.
HIV Type-1 Pipeline
HIV Type-1 Pipeline Insight – 2024
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key
HIV type-1
companies, including United BioPharma, Gilead sciences, Taimed Biologics, Merck Sharp &Dohme, Janssen Sciences, CytoDyn Biosciences, MacroGenics,
among others.
About
DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Shruti Thakur
[email protected]
+14699457679
Logo:
SOURCE DelveInsight Business Research, LLP
MENAFN30082024003732001241ID1108620869